Targeting triple-negative breast cancer: optimising therapeutic outcomes
Annals of Oncology, 05/04/2012Gelmon K et al.
The use of biological preselection to guide therapy will improve therapeutic indices in target–bearing populations. Ongoing clinical trials of targeted agents in unselected triple–negative breast cancer (TNBC) populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target–selected populations.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.